Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Post by ForexWhaleon Jan 31, 2019 9:11pm
150 Views
Post# 29304510

New is out. PP announced

New is out. PP announced
iCo Therapeutics arranges $750,000 private placement 2019-01-31 20:13 ET - News Release

Shares issued 84,457,713 ICO Close 2019-01-31 C$ 0.055

Mr. Andrew Rae reports ICO THERAPEUTICS INC. ANNOUNCES NON-BROKERED PRIVATE PLACEMENT TO RAISE C$750,000 iCo Therapeutics Inc. has issued a total of three million units pursuant to the first tranche of a non-brokered private placement. The company plans to issue up to 15 million units at a price of five cents per unit for total gross proceeds of $750,000, pursuant to the private placement. Each unit will consist of one common share in the capital of the company and one common share purchase warrant, exercisable at 7.5 cents for 36 months from the date of the closing of the private placement. The warrants are subject to an acceleration clause that allows the company to accelerate the expiry date of the warrants. In the event that, at any time after four months from the closing date, the volume weighted average trading price of the common shares on the TSX Venture Exchange equals or exceeds 14 cents for 10 consecutive trading days, the warrants will expire on the date that is at least 30 days following the issuance of a press release announcing such acceleration from the company.
<< Previous
Bullboard Posts
Next >>